Georg Richtig (G Richtig)

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 14

Top Topics

Cross Sectional

Top Venues

Journal of the European Academy of Dermatology and Venereology : JEADV

The British journal of dermatology

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Lukas Buchacher, Georg Richtig, Marie Dernoscheg, Erika Richtig, Lukas Koch
Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
L Buchacher, Georg Richtig, M Dernoscheg, E Richtig, Lukas Koch
Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Georg Richtig, Erika Richtig
New ways to strengthen old risk factors. Journal of the European Academy of Dermatology and Venereology : JEADV 38 (1) (2023)
Georg Richtig, Erika Richtig
New ways to strengthen old risk factors. Journal of the European Academy of Dermatology and Venereology : JEADV 38 (1) (2023)
Georg Richtig, Marina Berger, Max Koeller, Markus Richtig, Erika Richtig, Jörg Scheffel, Marcus Maurer, Frank Siebenhaar
Predatory journals: Perception, impact and use of Beall's list by the scientific community-A bibliometric big data study. PloS one 18 (7) (2023)
L Buchacher, Georg Richtig, C Schöffl, E Richtig, Lukas Koch
Long-term adherence to melanoma follow-up examinations - a telephone survey. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (9) (2022)
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A Nebhan, Ibiayi Dagogo-Jack, Nathaniel J Myall, Georg Richtig, Jillian Wilhelmina Paulina Bracht, Marco Gerlinger, Eiji Shinozaki, Takayuki Yoshino, Daisuke Kotani, Jason R Fangusaro, Oliver Gautschi, Julien Mazieres, Jeffrey A Sosman, Edmund S Kopetz, Vivek Subbiah, Michael A Davies, Anna L Groover, Ryan J Sullivan, Keith T Flaherty, Douglas B Johnson, Andrea Benedetti, David W Cescon, Anna Spreafico, George Zogopoulos, April A N Rose
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. JCO precision oncology 6 (2022)
Georg Richtig, L Cerroni, H Schmidt, C Beham-Schmid, Teresa Kränke, C Vallant, E Richtig
Talimogene laherparepvec can initiate plasma cell invasion into infiltrated melanoma lesions - a case series. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (3) (2020)
Georg Richtig, Alena M Aigelsreiter, Martin Asslaber, Thomas Weiland, Martin Pichler, Katharina Eberhard, Stephan Sygulla, Silvia Schauer, Gerald Hoefler, Ariane Aigelsreiter
Hedgehog pathway proteins SMO and GLI expression as prognostic markers in head and neck squamous cell carcinoma. Histopathology 75 (1) (2019)
Georg Richtig, E Ramelyte, L Koch, H Greinix, S Ferrone, R Dummer, E Richtig
Unmasking of a primary desmoplastic melanoma tumour in the course of treatment of a metastatic disease with anti-PD-1 monoclonal antibody. Journal of the European Academy of Dermatology and Venereology : JEADV 33 (10) (2019)
Georg Richtig, Christoph Hoeller, Martin Wolf, Ingrid Wolf, Barbara M Rainer, Günter Schulter, Markus Richtig, Martin R Grübler, Anna Gappmayer, Thomas Haidn, Julian Kofler, Rainer Huegel, Bernhard Lange-Asschenfeldt, Martin Pichler, Stefan Pilz, Akos Heinemann, Erika Richtig
Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study. PloS one 13 (10) (2018)
Georg Richtig, E Richtig, K Kashofer, L Koch, G Winter, G Hoefler, M Pichler, B Ehall, M R Grübler, A Heinemann, A Aigelsreiter
Testing and clinical implications for non-V600 BRAF mutations in metastatic NRASmt melanoma. The British journal of dermatology 177 (3) (2017)
Georg Richtig, C Hoeller, K Kashofer, A Aigelsreiter, A Heinemann, L N Kwong, M Pichler, E Richtig
Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients. The British journal of dermatology 177 (4) (2017)
Georg Richtig, Ariane Aigelsreiter, Daniela Schwarzenbacher, Anna Lena Ress, Jan Basri Adiprasito, Verena Stiegelbauer, Gerald Hoefler, Silvia Schauer, Tobias Kiesslich, Peter Kornprat, Thomas Winder, Florian Eisner, Armin Gerger, Herbert Stoeger, Rudolf Stauber, Carolin Lackner, Martin Pichler
SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types. PloS one 12 (11) (2017)